KCNQ1 Human shRNA Plasmid Kit (Locus ID 3784)
CAT#: TL303806
KCNQ1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector, 5µg of each construct provided
Need custom shRNA service?
Get a free quote
CNY 5,740.00
货期*
现货
规格
Cited in 1 publication. |
Product images
经常一起买 (4)
Lateral flow testing sticks used for the semi-quantitative detection of the lentiviral p24 protein, 20 tests
CNY 4,070.00
Specifications
Product Data | |
Product Name | KCNQ1 Human shRNA Plasmid Kit (Locus ID 3784) |
Locus ID | 3784 |
UniProt ID | P51787 |
Synonyms | ATFB1; ATFB3; JLNS1; KCNA8; KCNA9; Kv1.9; Kv7.1; KVLQT1; LQT; LQT1; RWS; SQT2; WRS |
Vector | pGFP-C-shLenti |
Format | Lentiviral plasmids |
Kit Components | KCNQ1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 3784). 5µg purified plasmid DNA per construct29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free. |
RefSeq | NM_000218, NM_181797, NM_181798, NR_040711, NM_181798.1, NM_000218.1, NM_000218.2, NM_181797.1, BC113545, BC017074, BC111847, NM_000218.3 |
Summary | This gene encodes a voltage-gated potassium channel required for repolarization phase of the cardiac action potential. This protein can form heteromultimers with two other potassium channel proteins, KCNE1 and KCNE3. Mutations in this gene are associated with hereditary long QT syndrome 1 (also known as Romano-Ward syndrome), Jervell and Lange-Nielsen syndrome, and familial atrial fibrillation. This gene exhibits tissue-specific imprinting, with preferential expression from the maternal allele in some tissues, and biallelic expression in others. This gene is located in a region of chromosome 11 amongst other imprinted genes that are associated with Beckwith-Wiedemann syndrome (BWS), and itself has been shown to be disrupted by chromosomal rearrangements in patients with BWS. Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Aug 2011] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Citations (1)
The use of this RNAi has been cited in the following citations: |
---|
Suppression-Replacement KCNQ1 Gene Therapy for Type 1 Long QT Syndrome
,Dotzler, SM;Kim, CSJ;Gendron, WAC;Zhou, W;Ye, D;Bos, JM;Tester, DJ;Barry, MA;Ackerman, MJ;,
Circulation
,PubMed ID 33504163
[KCNQ1]
|
Documents
Product Manuals |
FAQs |
SDS |
Customer
Reviews
Loading...